Source comparison
Compounded vs FDA-Approved Formulations: Budget Implications
Tesamorelin is FDA-approved as Egrifta (and Egrifta SV) for HIV-associated lipodystrophy, with branded pricing ranging from $4,500–$6,000 per month before insurance. A cost structure that positions compounded formulations as the primary access route for resear
This comparison does not assign a generated winner or score.
- Tesamorelin is FDA-approved as Egrifta (and Egrifta SV) for HIV-associated lipodystrophy, with branded pricing ranging from $4,500–$6,000 per month before insurance. A cost structure that positions compounded formulations as the primary access route for research and off-label use. Compounded Tesamorelin prepared by FDA-registered 503B facilities uses the same acetate salt and lyophilized powder format but costs 92–96% less due to the absence of brand markup and FDA-mandated clinical trial cost recovery. The pharmacological mechanism. GHRH receptor agonism leading to increased pituitary GH secretion. Is identical whether the peptide originates from Theratechnologies or a licensed compounding pharmacy.
- Ipamorelin has no FDA-approved formulation for any indication, making all clinical and research use inherently compounded. This regulatory gap means pricing variability is higher for Ipamorelin than for Tesamorelin. Compounding pharmacies set rates based on raw peptide sourcing cost, synthesis batch size, and competitive positioning rather than reference pricing against a branded equivalent. Quality verification becomes the primary differentiator: high-purity Ipamorelin synthesized with exact amino acid sequencing and verified by HPLC (high-performance liquid chromatography) costs $80–$140 per 5mg vial, while lower-tier sources may offer $45–$60 pricing with less rigorous purity documentation.
- Our experience reviewing third-party certificates of analysis shows that advertised purity percentages (e.g., '98% pure Ipamorelin') don't guarantee therapeutic equivalence. The remaining 2% could include acetate salts and excipients (acceptable) or peptide fragments and synthesis byproducts (problematic). Real Peptides commits to small-batch synthesis with verified amino acid sequencing for every peptide in our research catalog, including CJC1295 Ipamorelin 5MG 5MG formulations that pair well with Tesamorelin protocols targeting comprehensive growth hormone optimization.